No Data
Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Stoke Therapeutics (STOK) and Lantheus (LNTH)
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $22 to $47
Biogen and Stoke Therapeutics to Commercialise Dravet Syndrome Treatment
Stoke Therapeutics Partners With Biogen for Zorevunersen
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Stoke Therapeutics Price Target Raised to $47.00/Share From $35.00 by HC Wainwright & Co.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
